Corcuera-Munguia Marta, Gil-Prieto Ruth, Garcia-Carretero Rafael, Gil-de-Miguel Angel
Department of Medical Specialities and Public Health. Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain.
Department of Medical Specialities and Public Health. Area of Internal Medicine, Rey Juan Carlos University, Madrid, Spain.
Infect Dis Ther. 2023 Jan;12(1):143-156. doi: 10.1007/s40121-022-00717-6. Epub 2022 Nov 8.
Herpes zoster (HZ) and its complications still represent a significant burden for patients and health care systems. In Spain, vaccination is progressively being introduced and recommended for patients between 65 and 80 years old and patients > 18 years of age suffering from certain immunosuppression conditions. The aim of this study is to estimate the number of hospital admissions related to HZ from 2016 to 2019 in Spain.
Data were collected from the Minimum Basic DataSet (MBDS) and codified according to the Spanish version of the 10th International Classification of Disease (ICD-10-CM codes B02-B02.9). Among others, variables such as sex, age and presence of complications were included.
A total of 27,642 hospitalizations were identified (90% in patients > 50 and 45.8% in patients > 80). Women represented 51.2% of the patients, and 59.9% of patients presented complications related to HZ. The hospitalization rate was 17.74, the mortality rate was 1.2, and the case fatality rate was 6.75%. All rates were significantly higher with age, among men and in complicated HZ. Immunosuppression status for which vaccination had been recommended represented 22.7% of the total cases, affecting mostly individuals > 65 and causing more deaths in those > 80 years. The estimated annual cost of hospitalization for herpes zoster was €35,738,285, and the mean cost per patient was €5172.
The hospitalization burden for HZ is still important in Spain. Data on the current epidemiology are important to evaluate future vaccination strategies.
带状疱疹（HZ）及其并发症仍然给患者和医疗保健系统带来沉重负担。在西班牙，疫苗接种正逐步推广，并建议65至80岁的患者以及患有某些免疫抑制疾病的18岁以上患者接种。本研究的目的是估计2016年至2019年西班牙与HZ相关的住院人数。
数据从最低基本数据集（MBDS）收集，并根据第10版国际疾病分类的西班牙版本（ICD-10-CM编码B02-B02.9）进行编码。其中包括性别、年龄和并发症等变量。
共确定了27642例住院病例（50岁以上患者占90%，80岁以上患者占45.8%）。女性占患者总数的51.2%，59.9%的患者出现与HZ相关的并发症。住院率为17.74，死亡率为1.2，病死率为6.75%。所有比率在年龄较大者、男性和HZ并发患者中均显著更高。建议接种疫苗的免疫抑制状态占总病例的22.7%，主要影响65岁以上人群，且80岁以上人群死亡更多。带状疱疹住院的估计年度费用为35738285欧元，每位患者的平均费用为5172欧元。
在西班牙，HZ的住院负担仍然很重。当前的流行病学数据对于评估未来的疫苗接种策略很重要。
